HUM — Humana Inc.
Is HUM overbought or oversold? Here is the current MarketMoodz read.
Humana Inc. (HUM) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Healthcare Plans) last closed at $461.25. The rating moved from Neutral to Overbought on November 13, 2026.
- Public ratingOverbought (as of November 17, 2026)
- Last close$461.25
- Last changeMoved from Neutral to Overbought on November 13, 2026
- SectorHealthcare
- IndustryHealthcare Plans
See all overbought Healthcare stocks →
AI analysis
Humana benefits from a strong Medicare Advantage position, scale in care management and demographic-driven demand, supporting durable cash flows and earnings visibility. Key near-term catalysts include membership growth, stable risk-adjustment execution and margin management during competitor benefit expansions. However, political and regulatory developments targeting vertical integration and aggressive MA pricing pose material near- to medium-term policy risk. The balance of solid fundamentals and identifiable policy/execution risks supports modest upside over the next month, contingent on continued disciplined cost management and absence of adverse regulatory action.
Key factors
- Leading Medicare Advantage franchise with sustained membership growth and favorable demographic tailwinds (aging U.S. population).
- Demonstrated ability to manage benefits and medical cost trends via care-management programs, network contracting and risk adjustment expertise.
- Defensive large-cap healthcare flows supporting relative performance in uncertain macro/regulatory windows.
- Scale advantages across MA product design, provider relationships and administrative infrastructure that support margin resilience.
- Conservative recent disclosures (neutral 8-K), and no immediate volatility in the last trading window, allowing focus on fundamentals and earnings follow-through.
Risks
- Heightened regulatory and antitrust scrutiny of vertically integrated healthcare (e.g., proposed Break Up Big Medicine Act) that could increase compliance costs, constrain strategic options or force structural changes.
- Competitive pressure and margin compression from industry-wide moves to $0-premium Medicare Advantage offerings and richer benefits if competitors accelerate aggressive pricing.
- Policy or reimbursement changes at the federal level (Medicare/Medicaid) that could reduce revenue or change risk-adjustment dynamics.
- Execution risk managing medical cost trends (utilization, specialty drug spend) and preserving underwriting discipline while pursuing growth.
- Concentration risk relative to other large integrated payors that could amplify sector-specific shocks or adverse readthroughs from peers.
Latest MarketMoodz coverage
- Humana Tops Overbought List as Healthcare Outperforms Tech2026-06-13
- Cisco Hits RSI 90 — Most Overbought S&P 500 Stock2026-05-16
- CMS Finalizes 2.48% Medicare Advantage Hike for 2027, Lifts Insurer Stocks2026-04-07
- Levi's Earnings in Focus as Retail and Macro Catalysts Converge2026-04-06
- Trump administration finalizes 2.48% 2027 Medicare Advantage rate; insurers rally2026-04-06
See today's live rating, score and targets
Members see the live hourly rating for HUM — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.